We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Polymeric Strand Replaces Platinum in Aneurysm Coiling Procedures

By HospiMedica International staff writers
Posted on 19 Apr 2011
A novel aneurysm-treatment system will offer physicians an alternative solution to platinum coils in the treatment of large, giant, and wide-neck cerebral aneurysms, which are typically the most challenging to treat.

The cPAX aneurysm-treatment system provides effective embolization of large and giant cerebral aneurysms using an 85-cm long polymeric strand delivered through a microcatheter into a cerebral aneurysm over a guide wire. More...
The soft, flexible material allows for increased packing density, providing conformable filling and increased packing density when compared to platinum coils. The continuous filling capability contributes to a reduction in the amount of devices necessary to complete the procedure, as well as the time required for treatment. Due to its soft polymeric material, it may also provide a more complete filling of the aneurysm and greater long-term stability.

Unlike platinum coils, which have a fixed detachment zone, the cPAX can detach at any point chosen by the clinician. The continuous filling capability of the product also decreases both the number of devices and the amount of time required for treatment. The polymeric material also allows for noninvasive magnetic resonance imaging (MRI) and computed tomography (CT) scans without metallic artifact, allowing for better patient follow-up assessment. The cPAX system, a product of NeuroVASx (Maple Grove, MN, USA), has been approved by the US Food and Drug Administration (FDA) as a humanitarian use device for the treatment of cerebral aneurysms.

"This FDA approval brings an important cutting-edge technology to a patient population that is currently underserved,” said Eric Timko, president and CEO of NeuroVasx. "We are excited to offer this treatment to patients and we look forward to working with our key physicians to bring this product to market.”

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain, which can be caused by several factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use, or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain; approximately 40% of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery using minimally invasive techniques.

Related Links:

NeuroVASx



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Medical-Grade Display
HL2316SHTB
New
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.